A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Recruiting now · Phase 1

Conditions studied: Locally Advanced (Unresectable) or Metastatic Solid Tumors

In brief

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Key facts

Study ID

NCT07612176

Run by

NEOK Bio, Inc.

People needed

155

Starts

2026-04-21

Expected to finish

2029-01-01

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NEXT Oncology — San Antonio, Texas, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
• NEXT Oncology — Dallas, Texas, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• NEXT Oncology — Houston, Texas, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• NEXT Oncology — Fairfax, Virginia, United States
• NEXT Oncology — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.